Biocon informs about company statement

08 Sep 2021 Evaluate

Biocon has informed that the company and its subsidiaries Biocon Pharma \ and Biocon Pharma Inc. (‘Biocon’) has entered into a confidential settlement agreement with Celgene Corporation (Celgene), a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID® (lenalidomide).” The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

370.10 -9.60 (-2.53%)
27-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.65
Dr. Reddys Lab 1281.95
Cipla 1242.65
Zydus Lifesciences 896.60
Lupin 2334.95
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×